This study is looking at people with gastrointestinal cancers, which are cancers that affect the digestive system. The types of cancer included in this study are pancreatic ductal adenocarcinoma, which is a cancer of the pancreas, cholangiocarcinoma, which is cancer of the bile ducts, gallbladder cancer, colorectal adenocarcinoma, which is cancer of the colon or rectum, gastric adenocarcinoma, which is stomach cancer, gastroesophageal junction adenocarcinoma, which is cancer where the stomach meets the esophagus, and esophageal adenocarcinoma, which is cancer of the esophagus. These cancers must be unresectable, meaning they cannot be removed by surgery, or metastatic, meaning they have spread to other parts of the body. The treatment being studied is called Raludotatug Deruxtecan, which is also known by the code name MK-5909. This medication is given through an intravenous infusion, which means it is delivered directly into a vein.
The purpose of this study is to evaluate how safe and effective Raludotatug Deruxtecan is in treating these types of gastrointestinal cancers. The study will look at whether the treatment helps to shrink the tumors and how long any improvement lasts. The study will also collect information about any side effects or unwanted reactions that people may experience while receiving the treatment. People taking part in this study will have already received previous treatment for their cancer before joining.
During the study, participants will receive the study medication for up to 12 months. Doctors will monitor how the cancer responds to the treatment and will check for any side effects. The study will measure things like whether the tumors get smaller, how long the treatment works, how long people live without their cancer getting worse, and overall survival. This is an open-label study, which means that both the doctors and the participants will know what treatment is being given.
France 
Spain 
